Business
Mar 17, 2026
第一排 第二排 第三排 第四排
Inspiring Confidence in Every Dose
Accessible, high-quality medicine you can trust—delivered with excellence and care since 1966.
OUR VISION
We believe access to medicine is a fundamental right, not a privilege. We aspire to deliver the right pharmaceutical products to patients across the globe.
OUR MISSION
We strive to enhance global access to medicine through a diverse portfolio of products. Our goal is to be a trusted employer, partner, supplier, and sound investment—earning and inspiring confidence at every step.
Our Milestones
1966
2014
2019
2020
2021
2022
2024
2025
Founded in Taiwan
Lotus and Alvogen merge Asian operations
Lotus launched its first P4 product Buprenorphine/naloxone in the US.
Qsymia® launch in Korea
Petroleum Authority of Thailand (PTT) invested in Lotus, strategic partnership in southeast Asia
Lotus launched Lenalidomide in the US; Acquisition of Alimta® and Cialis® from Eli Lilly for Taiwan
Acquisition of Teva pharma Thailand; Acquisition of Alpha Choay ® from Sanofi for Vietnam
Acquisition of Alvogen US, creating a top 20 global specialty pharma powerhouse
Commitment to Quality
Certified by leading global regulatory authorities—including the U.S. FDA, EU EMA, Japan PMDA, Taiwan TFDA, China NMPA, and Brazil ANVISA—our manufacturing sites meet the highest global standards for safety, efficacy, and quality of our products.
We uphold rigorous quality management across every stage of production and cultivate a company‑wide culture where quality is foundational. This commitment ensures our products consistently earn the trust of patients, healthcare providers, and global partners.
Here are a few articles that you might find interesting
縮排測試
Business
Feb 24, 2026
Taipei, Taiwan, 24 February 2026 — Lotus Pharmaceutical Co., Ltd. (Taiwan Stock Exchange: 1795), a leading global pharmaceutical company, today announced that it has filed a New Drug Application (“NDA”) under the 505(b)(2) regulator...
Business
Feb 23, 2026
Solaxa and Alvogen enter into license agreement for the development and commercialization of SLX-100 for spinocerebellar ataxia type 27B (SCA27B) Alvogen will acquire worldwide rights for SLX-100 for SCA27B and will be responsible for the co...
